Abstract 4722
Background
HER2+ occurs in 15-20% of BC and is associated with worse prognosis. While previous studies reported that NAT-associated changes in HER2 status adversely affect patients (pts) prognosis (Guarneri et al), others did not (Yoshida et al). To assess the efficacy of NAT in pts with HER2+ BC and its influence on HER2 status and associated prognostic impact. HER2 status was determined by immunohistochemically (IHC) or Silver in situ hybridization (SISH).
Methods
Retrospective chart review and pathologic evaluation of all consecutive pts with HER2+ BC (defined as IHC 3+ or IHC 2+ confirmed by SISH) submitted to NAT between Jan2010 and Oct2015 in 3 Portuguese Hospitals. All diagnostic tumor biopsies and surgical specimens were assessed for IHC.
Results
108 female pts were included (median age 52yo, range 30-82; TNM stage was III in 68, II in 40. Hormone receptor (HR) were positive (ER and/or PR) in 68. HER2 status at diagnosis was IHC 3+ in 100 pts and IHC 2+ SISH amplified in 8. NAT included chemotherapy (CT) in all pts (anthracyclines (AC)/ taxanes (Tax) 102, AC/non-Tax 3, non-AC regimen 3), trastuzumab (T) in 87 and T and pertuzumab (P) in 3. Pathological complete response (pCR) (ypT0/isN0) was achieved in 48 pts (44.4%): 28 of 70 HR+ and 20 of 38 HR neg (p = 0.2), 27 of 40 with stage II and 21 of 68 with stage III (p < 0.001). pCR rate was 46% after CT+T/P and 39% with CT alone (p = 0.6). With a median follow-up of 55 months, there were 5 disease free survival (DFS) events (4 relapses and 1 non-BC death) among pCR pts and 19 among non-pCR (16 relapses and 3 non-BC deaths) (p = 0.02, log rank test). Of the 60 pts with residual invasive tumor at surgery, 52 remained HER2+ and 8 (13.3%) lost Her2+. 5y-DFS and 5-OS is 70% and 84%, respectively, for pts whose tumors remained HER2 + (14 DFS events; 8 deaths), and 21% and 50% for pts whose residual tumors became HER2 negative (5 DFS events; 4 deaths) (p = 0.02 and <0,001, log-rank test).
Conclusions
We confirmed the negative prognostic impact of NAT-induced HER2 loss on residual tumor leading to worse DFS. Despite the retrospective design and small sample size, these results suggest the importance of retesting HER2 after NAT, to better refine pts prognosis.
Clinical trial identification
Legal entity responsible for the study
José Luís Passos Coelho.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract